Cargando…

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

BACKGROUND: Most melanoma patients with BRAF(V600E) positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the treatment. For patients insufficiently resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cesi, Giulia, Walbrecq, Geoffroy, Zimmer, Andreas, Kreis, Stephanie, Haan, Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465587/ https://www.ncbi.nlm.nih.gov/pubmed/28595656 http://dx.doi.org/10.1186/s12943-017-0667-y

Ejemplares similares

Transferring intercellular signals and traits between cancer cells: extracellular vesicles as “homing pigeons”
por: Cesi, Giulia, et al.
Publicado: (2016)

Phosphorylation of the pyruvate dehydrogenase complex precedes HIF-1-mediated effects and pyruvate dehydrogenase kinase 1 upregulation during the first hours of hypoxic treatment in hepatocellular carcinoma cells
por: Zimmer, Andreas David, et al.
Publicado: (2016)

Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells
por: Margue, Christiane, et al.
Publicado: (2019)

Distinct Cargos of Small Extracellular Vesicles Derived from Hypoxic Cells and Their Effect on Cancer Cells
por: Walbrecq, Geoffroy, et al.
Publicado: (2020)

Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles
por: Walbrecq, Geoffroy, et al.
Publicado: (2020)

A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells
por: Cesi, Giulia, et al.
Publicado: (2018)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

Metabolic rewiring in melanoma
por: Ratnikov, Boris I., et al.
Publicado: (2016)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
por: Baenke, Franziska, et al.
Publicado: (2015)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
por: Tietze, Julia K., et al.
Publicado: (2018)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

BRAF inhibitors: resistance and the promise of combination treatments for melanoma
por: Griffin, Merope, et al.
Publicado: (2017)

Metabolic rewiring directs melanoma immunology
por: Sun, Ningyue, et al.
Publicado: (2022)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma
por: Parker, Robert, et al.
Publicado: (2015)

BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells
por: Karki, Prashant, et al.
Publicado: (2021)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2018)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Rewiring the cell
por: Wells, William A.
Publicado: (2004)

DTL promotes melanoma progression through rewiring cell glucose metabolism
por: Lu, Jia-Jing, et al.
Publicado: (2022)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
por: Xiao, Jingjing, et al.
Publicado: (2018)

ROCK inhibitor enhances the growth and migration of BRAF‐mutant skin melanoma cells
por: Chang, Fei, et al.
Publicado: (2018)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
por: Guzzetti, Carlotta, et al.
Publicado: (2023)

Connecting Metabolic Rewiring With Phenotype Switching in Melanoma
por: Falletta, Paola, et al.
Publicado: (2022)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Recombinant Interleukin-24 Lacks Apoptosis-Inducing Properties in Melanoma Cells
por: Kreis, Stephanie, et al.
Publicado: (2007)

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2019)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
por: Salzmann, Martin, et al.
Publicado: (2020)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
por: Savoia, Paola, et al.
Publicado: (2020)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
por: Mezi, Silvia, et al.
Publicado: (2023)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hu3u8f6f86tmcttc6kr4h138os